Research and development contract - proposal JW220021 - contract proposal title - evaluating the safety and ease of use of counterflow hemostatic gauze for extreme cold environments
Active Definitive Contract Awarded Last action
- Contract number
- HT942523C0095
- Awardee
-
Versiti Blood Health, Inc. UEI JZDRNT166LE4
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $6,485,297
Award facts
- Opportunity
-
- W81XWH22SJWMR Solicitation number
- Contract value 100% obligated
- $6,485,297.00 Current and potential, with all options
- Completion date 94% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Basic Research
- Pricing
- Cost No Fee
- Place of performance
- Milwaukee, WI 53201, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Change Order | $0 | |
| Change Order | $0 | |
| Change Order | $0 | |
| Supplemental Agreement for work within scope | $1,985,297 | |
| Original award | $4,500,000 |
About this award
The Defense Health Agency awarded a $6.485 million definitive contract to Versiti Blood Health, Inc. on September 25, 2023, for research and development to evaluate the safety and ease of use of counterflow hemostatic gauze for extreme cold environments, with ultimate completion on December 24, 2026.
The contract carries cost-plus-no-fee pricing and was issued without set-aside. Place of performance is Milwaukee, WI.
The research program encompasses protocol approvals, efficacy testing of counterflow gauze compared to combat gauze and standard gauze with intravenous tranexamic acid (TXA) in a swine hemorrhage model at extreme cold (-10 degrees Celsius), development of analytical and bioanalytical methods for thrombin and TXA assessment, FDA regulatory submissions including Investigational Device Exemption and Investigational New Drug applications, establishment of Good Manufacturing Practice manufacturing processes, and production of pilot batches up to 2,400 units for preclinical and safety testing. Major subcontractors include ST Michael's Hospital for in vivo efficacy studies in extreme cold environments and Comotion Drug Delivery Systems Inc. for analytical method development, regulatory submissions, and GMP manufacturing scale-up with equipment upgrades and barium thread integration processes.
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| ST Michael's Hospital | $699,941 | |
| Comotion Drug Delivery Systems Inc. | $899,989 | |
| Comotion Drug Delivery Systems Inc. | $1,800,000 |
Quick answers
Who was awarded contract HT942523C0095?
HT942523C0095 was awarded to Versiti Blood Health, Inc. by Defense Health Agency (Department of Defense) on September 25, 2023.
How much is contract HT942523C0095 worth?
The government has obligated $6,485,297 on HT942523C0095.
Was contract HT942523C0095 competed?
The extent of competition for HT942523C0095 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award